Published on
Jul 28, 2026
Pentixapharm raises €20.4M for Phase 3 diagnostic trial
Why it matters: The financing gives Pentixapharm the funds to test whether a noninvasive scan can help doctors choose between surgery and drug treatment for patients with primary hyperaldosteronism, also known as Conn’s syndrome, a condition that occurs …
Source:
European Biotechnology
-
Neutral
